readthroughSign in
Nov 13, 2026Quarterly update

Tvardi reports Q3 2026 results, preps TTI-109 move into ulcerative colitis trial

Houston biotech says Phase 1 data support advancing its STAT3 inhibitor prodrug into UC, while HCC topline data from TTI-101 are expected early in Q1 2027.

Tvardi Therapeutics reported financial results and a business update for the third quarter ended September 30, 2026, on November 13, 2026.

The company said it is preparing to advance TTI-109 into clinical development in ulcerative colitis, subject to clearance of an Investigational New Drug application and additional funding, building on positive Phase 1 healthy volunteer results reported in July and the selection of UC as its initial target indication.1 Those Phase 1 findings confirmed the prodrug design, showing TTI-109 delivering TTI-101-equivalent exposure with improved tolerability, and across the active dose range showed reductions in cellular and humoral immune populations linked to UC severity, offering pharmacodynamic evidence of STAT3 target engagement.1

Tvardi also cited new preclinical data published in the International Journal of Molecular Sciences, in which TTI-101 reached colon tissue exposure roughly eightfold higher than plasma in a chronic colitis model, normalized colitis-related gene expression changes, reduced microbiome disruption and prevented colon adenocarcinoma formation, a long-term consequence of chronic colitis.1

On the oncology side, the company is advancing its Phase 1b/2 REVERT LIVER CANCER study evaluating TTI-101 as monotherapy and in combination with established therapies in hepatocellular carcinoma, with topline data expected early in the first quarter of 2027 to allow complete cohort evaluation.1

Listed milestones include initiation of a clinical trial of TTI-109 in UC in 2027, subject to IND clearance and additional funding, and TTI-101 Phase 1b/2 HCC topline data in early first quarter of 2027.1

On finances, cash and cash equivalents were $22.3 million as of September 30, 2026, compared with cash, cash equivalents and short-term investments of $30.8 million as of December 31, 2025.1 The company said existing cash is expected to fund operations, as currently planned, into the third quarter of 2027.1 It added that advancing TTI-109 into UC and additional indications remains subject to additional funding and IND clearance.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.